Indication
Hematologic Malignancy
4 clinical trials
12 products
1 drug
Product
Inotuzumab ozogamicinClinical trial
Korean Post Marketing Surveillance Study to Observe Safety and Effectiveness of BESPONSA (REGISTERED)Status: Active (not recruiting), Estimated PCD: 2025-01-02
Product
TafasitamabClinical trial
ARIA: A Phase 1b/2, Open-label, Multi Cohort Trial of Tazemetostat in Combination With Various Treatments in Subjects With Relapsed or Refractory Hematologic MalignanciesStatus: Withdrawn, Estimated PCD: 2023-07-05
Product
DaratumumabClinical trial
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaStatus: Recruiting, Estimated PCD: 2026-08-01
Product
ibrutinibProduct
TazemetostatProduct
LenalidomideProduct
AcalabrutinibProduct
EmavusertibProduct
Hyaluronidase-FihjProduct
DexamethasoneProduct
MosunetuzumabProduct
PomalidomideClinical trial
A Pilot Trial of Atorvastatin in p53-Mutant and p53 Wild-Type MalignanciesStatus: Active (not recruiting), Estimated PCD: 2022-10-14
Drug
Atorvastatin